StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Recent CTV News Article

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Feb 16, 2021 9:58am

153 Views

Post# 32572238

RE:RE:RE:RE:RE:RE:RE:Recent CTV News Article

On page 32-333 of the prospectus filed in November. These are the 4 objectives and costs/dates.

It says the objective is to hire to achieve 3,000 tests per day in December/January and exceed 3,000 tests per day 3-6 months after.

1) Hire additional full-time employees to assist with COVID-19 and Aristotle® testing capabilities Fully staffed lab with validated equipment; capable of processing 3,000 COVID-19 Tests (comprising either PCR tests, or antibody tests, or both) per day December 2020 or January 2021 $1,335,000 to $2,670,000 (to be funded by proceeds of the Offering) 33 Objective Milestones Timing Remaining Cost

2) Increase COVID-19 Tests capability above 3,000 tests (comprising either PCR tests, or antibody tests, or both) per day. Purchase additional equipment and supplies. Three (3) to six (6) months $950,000 to $1,900,000 (to be funded by proceeds of the Offering)

3) Increase advertising and marketing for Aristotle® Increase advertising and marketing initiatives for Aristotle® Six (6) to nine (9) months $600,000 to $3,000,000 (to be funded by proceeds of the Offering)

4) Expand Richmond Laboratory space Renegotiate lease to expand Richmond Laboratory space by 5,000 square feet Six (6) months $180,000 (to be funded by proceeds of the Offering
--------

I justy dont understand why we cant get any interim updates on these major objectives. Is it just 1 monsterous NR about Aristotle and nothing else??

I posted about CBDT becuase of how they are building momentum with halts and news and building their company. They already have a market cap double ours.